RE:RE:WowLast short squeeze was very similar. Yet 5 yrs ago. Went from under $1 to over $5 in a few weeks. This time IS Different! They are in writing talking about accelerated approval. THAT , is the brass ring for onc. Any approval, would move oncolytics biotech from development stage to marketing stage. Going back 5 yrs, only had expectations of outcomes. Now, the pancreatic cancer co therapy alone, could move them to blockbuster status. Pancreatic cancer is almost a death sentence. The phase 2 results & reason for potential accelerated approval, showed some very substantial improvements over existing standard of care. The MBc which they do not yet have a partner or funding, is icing on the cake. Onc is a prime take over target. Ohalmost forget. They are in process of starting an add arm, funded from a $5million grant from PanCan, They have been superseded by CGAR, who is collaborating with the additional arm, alongside Roche. And The upcoming pancreatic cancer trial. Again, I direct those looking for information to go to oncolyitics web site. Great detail & explanation of the science. It is the science that will determine the ultimate value of Onc , not the day-day share price. Hard concept for many.